Skip to content

Study · Non-randomized trial · n = 24 · 2022

4 results

Effective ancillary role and long-term course of daily or weekly teriparatide treatment on refractory medication-related osteonecrosis of the jaw: a clinical case series.

Yoshiga D, Yoshioka I, Habu M, Sasaguri M, Tominaga K

The British journal of oral & maxillofacial surgery25 Oct 2021Cited by 9 (Europe PMC)

PMID34996629 (opens in a new tab)DOI10.1016/j.bjoms.2021.10.004 (opens in a new tab)PepBankPUB-34996629
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In refractory jaw osteonecrosis patients, healing was faster in the teriparatide groups than with conservative management without teriparatide.

    In plain wordsIn refractory jaw osteonecrosis patients, healing was faster with teriparatide than with conservative management alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseHealing period
    Study

    n = 24

    Comparator
    Standard conservative management without teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily or 56.5 μg weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The exposed bone was completely covered with normal mucosa in all patients in the TPTD groups, and the healing period was shorter than that in the non-TPTD group.
    4 context sentences
    Summary · context
    Three patients in the daily group did not complete the study, resulting in six patients in the daily group, nine in the weekly group, and nine in the non-TPTD group in the final analysis.
    Summary · context
    We enrolled 27 patients (January 2012 - December 2016) with chronic and refractory MRONJ.
    Summary · context
    Nine patients who did not select TPTD therapy for several reasons formed the non-TPTD group; the remaining 18 were randomly assigned to the daily (n=9) or weekly (n=9) groups.
    Summary · context
    All patients in both groups continued standard conservative therapy in addition to their daily or weekly subcutaneous injection of TPTD (20 μg or 56.5 μg, respectively).
  2. 02HumanNon-randomized trialEfficacy outcome

    In refractory jaw osteonecrosis patients, exposed bone became completely covered by normal mucosa in all analyzed teriparatide-treated patients.

    In plain wordsIn refractory jaw osteonecrosis patients, normal mucosa completely covered exposed bone in all analyzed teriparatide-treated patients.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseNormal mucosal coverage of exposed bone
    Study

    n = 15

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily or 56.5 μg weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The exposed bone was completely covered with normal mucosa in all patients in the TPTD groups, and the healing period was shorter than that in the non-TPTD group.
    4 context sentences
    Summary · context
    Three patients in the daily group did not complete the study, resulting in six patients in the daily group, nine in the weekly group, and nine in the non-TPTD group in the final analysis.
    Summary · context
    We enrolled 27 patients (January 2012 - December 2016) with chronic and refractory MRONJ.
    Summary · context
    Nine patients who did not select TPTD therapy for several reasons formed the non-TPTD group; the remaining 18 were randomly assigned to the daily (n=9) or weekly (n=9) groups.
    Summary · context
    All patients in both groups continued standard conservative therapy in addition to their daily or weekly subcutaneous injection of TPTD (20 μg or 56.5 μg, respectively).
  3. 03HumanNon-randomized trialOther

    In refractory jaw osteonecrosis patients assigned daily teriparatide, three patients did not complete the study.

    In plain wordsIn refractory jaw osteonecrosis patients assigned daily teriparatide, three patients did not complete the study.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableDaily-group noncompletion
    Study

    n = 9

    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    20 μg daily · subcutaneousAs given in this study (human).

    Measurements

    Noncompletion
    3 patients
    Daily teriparatide

    Source sentences

    Summary
    Three patients in the daily group did not complete the study, resulting in six patients in the daily group, nine in the weekly group, and nine in the non-TPTD group in the final analysis.
    3 context sentences
    Summary · context
    We enrolled 27 patients (January 2012 - December 2016) with chronic and refractory MRONJ.
    Summary · context
    Nine patients who did not select TPTD therapy for several reasons formed the non-TPTD group; the remaining 18 were randomly assigned to the daily (n=9) or weekly (n=9) groups.
    Summary · context
    All patients in both groups continued standard conservative therapy in addition to their daily or weekly subcutaneous injection of TPTD (20 μg or 56.5 μg, respectively).

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 04HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialSafety outcome

    In the refractory jaw osteonecrosis study, no patient had an atypical femoral head fracture complication.

    In plain wordsIn the refractory jaw osteonecrosis study, no patient had an atypical femoral head fracture complication.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableAtypical femoral head fractures
    Study

    n: not reported in source

    Outcome group
    Adverse events · Musculoskeletal

    Source sentences

    Summary
    No patient had complications of atypical fractures of the femoral head.
    3 context sentences
    Summary · context
    We enrolled 27 patients (January 2012 - December 2016) with chronic and refractory MRONJ.
    Summary · context
    Nine patients who did not select TPTD therapy for several reasons formed the non-TPTD group; the remaining 18 were randomly assigned to the daily (n=9) or weekly (n=9) groups.
    Summary · context
    All patients in both groups continued standard conservative therapy in addition to their daily or weekly subcutaneous injection of TPTD (20 μg or 56.5 μg, respectively).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.